Richard Kimani, MD
Internal Medicine · McMinnville, ORNPI 1417951849
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,875 of the $8,806 with a category attached, or 66.7%. Acadia Pharmaceuticals Inc accounts for 66.7% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2024 at $6,088 and has fallen 86.1% since, to $844 in 2025. Among internal medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $48.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$6K
- Amgen$390
- Pfizer$329
- Johnson & Johnson$245
- Novo Nordisk$244
- AstraZeneca$212
- plus $2K from 29 others
What the payments were for
- Consulting fees$5,87567%
- Food & beverage$2,90633%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 1 | $5,875 |
| Amgen(2 entities) | 22 | $390 |
| Pfizer | 24 | $329 |
| Johnson & Johnson(2 entities) | 20 | $245 |
| Novo Nordisk | 20 | $244 |
| AstraZeneca | 12 | $212 |
| AbbVie | 10 | $181 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $149 |
| Madrigal Pharmaceuticals | 3 | $111 |
| Lilly USA, LLC | 5 | $93 |
| Astellas Pharma US Inc | 5 | $86 |
| E.r. Squibb & Sons, L.L.C. | 6 | $82 |
| Shionogi Inc | 4 | $82 |
| Merck | 5 | $81 |
| Boehringer Ingelheim | 3 | $80 |
| GSK | 5 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| Exact Sciences | 2 | $46 |
| Vertex | 2 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Abbott | 2 | $37 |
| Bayer | 2 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Eisai Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Edwards Lifesciences | 1 | $19 |
| Philips North America LLC | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$5,875
How this compares
$8,806 in reported general payments places this provider in the 95th percentile of 1,363 internal medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 306 | $364,666 |
| JardianceEmpagliflozin | 364 | $290,740 |
| EliquisApixaban | 350 | $202,759 |
| JanuviaSitagliptin Phosphate | 145 | $136,301 |
| MyrbetriqMirabegron | 219 | $127,006 |
| ProliaDenosumab | 42 | $73,216 |
| RybelsusSemaglutide | 52 | $53,467 |
| XareltoRivaroxaban | 50 | $51,380 |
| Breo ElliptaFluticasone/Vilanterol | 88 | $48,033 |
| TrulicityDulaglutide | 40 | $45,002 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 83 | $39,508 |
| TradjentaLinagliptin | 45 | $36,378 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $33,808 |
| AptiomEslicarbazepine Acetate | 12 | $26,004 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 191 | $20,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $244 | $418,133358 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Synjardy Xr, Synjardy | $80 | $355,174465 claims |
| PfizerEliquis | $329 | $202,759350 claims |
| MerckJanuvia | $81 | $136,301145 claims |
| Astellas Pharma US IncMyrbetriq | $86 | $127,006219 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Arnuity Ellipta | $66 | $106,182164 claims |
| AmgenProlia | $390 | $73,21642 claims |
| Johnson & JohnsonXarelto | $245 | $51,38050 claims |
| Lilly USA, LLCTrulicity | $93 | $45,00240 claims |
| AstraZenecaFarxiga, Symbicort | $212 | $28,34550 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $23 | $26,00412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 internal medicine providers in Oregon.
Other internal medicine in McMinnville
- Chad PfeferBeaverton$639K
- Pranav ChandrashekarPortland$81K
- Jonathan EdmistonBend$68K
- Jessica CastlePortland$66K
- Ellen Schiaffino PurvisGresham$66K
- Steven ShawWhite City$58K
- Stephen SpurgeonPortland$42K
- Jane BabiarzPortland$30K
- Andrew HarbisonPortland$29K
- Marc UemuraEugene$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.